Tag: Glioblastoma

Lower LRIG1 Expression Linked to Aggressive Gliomas

November 12, 2025

“Our results reinforce suggestions that LRIG1-3 could function as diagnostic markers and therapeutic targets in the treatment of gliomas.” BUFFALO, NY - November 12, 2025 – A new research paper… read more

Oncotarget

New Radiofrequency Therapy Slows Glioblastoma Growth and Targets Tumor Stem Cells

October 14, 2025

“Intrabuccal administration of amplitude-modulated 27.12 MHz radiofrequency electromagnetic fields (AM RF EMF) resulting in the systemic delivery of low and safe levels of AM RF EMF has shown activity in… read more

Oncotarget

Triple Therapy Slows Glioblastoma Growth and Extends Survival in Preclinical Study

April 4, 2025

“Our findings demonstrate for the first time that IRT therapy combining ONC201 or ONC206 with RT and TMZ may be a safe and effective therapeutic strategy for GBM.” BUFFALO, NY… read more

Oncotarget

Engineered TIMP Molecules Show Potential to Slow Glioblastoma Brain Cancer Spread

March 3, 2025

"Given the lethal nature of GBM and the limited efficacy of current therapies, the application of TIMPs and their engineered minimal variants represents a novel and potentially transformative approach to… read more

Oncotarget

Zika Virus as a Treatment for Brain Cancer: A Systematic Review

October 9, 2024

“Despite limited human evidence, it shows potential benefits.” BUFFALO, NY- October 9, 2024 – A new review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Zika virus… read more

Oncotarget

Next-Gen Vaccines Offer New Hope Against Glioblastoma

September 9, 2024

“Vaccines have been considered a promising approach for GBM for many years.” BUFFALO, NY- September 9, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 5,… read more

Figure 1: From genome-wide CRISPR screen to the creation of combined predicting models.

Oncotarget

Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel

February 21, 2024

“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.” BUFFALO, NY- February 21, 2024 – A new research… read more

Figure 2: BCAS1+ cells in diffuse gliomas are morphologically different from BCAS1+ cells in healthy brain tissue.

Oncotarget

BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients

January 31, 2024

“[...] this is the first study describing a BCAS1+ cell population in a large cohort of diffuse glioma patients.” BUFFALO, NY- January 31, 2024 – A new research paper was… read more

Oncotarget

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines

January 17, 2024

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.” BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Oncotarget

GBP3-STING Interaction in Glioblastoma Coordinates Poor Response to Temozolomide

October 17, 2023

“The paper revealed a critical role of GBP3 involving multiple [temozolomide] resistance mechanisms.” BUFFALO, NY- October 17, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on… read more